Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease

The Cellular Therapy Network (TerCel)

Status and phase

Completed

Phase 2

Phase 1

Conditions

Intervertebral Disc Disease

Treatments

Procedure: Instrumented posterolateral arthrodesis

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01513694

CSM/Fusión/2009

Details and patient eligibility

About

The purpose of this trial is to test the effectiveness of the use of a new therapeutic strategy in treating patients with degenerative disc disease lumbar intervertebral fusion with instrumented posterolateral autologous mesenchymal stem cells and arranged in a calcium phosphate ceramic (Conduit TM).

Enrollment

15 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Clinical

Box symptomatic (back pain and / or root) of lumbar degenerative disc disease monosegmental.
Discopathy refractory to conservative treatment (drugs, physical therapy.)
Evolution greater than or equal to 6 months. Radiological
Discopathy radiation. Disc space narrowing, osteophytes, abnormal mobility, etc
NMR: grades IV and V of Pfirman.

Exclusion criteria

Rejection of surgical treatment.
Systemic inflammatory disease (spondylitis, rheumatoid arthritis etc), tumor or infection.
Immunosuppressive treatment.
Congenital or acquired anatomical abnormality that prevents the surgical procedure.
Neuropsychiatric pathology, drug addiction, psychosis, severe personality disorder.
High surgical risk (ASA> IV), or contraindication to anesthesia.